Ambulatory blood pressure response to S-amlodipine in Korean adult patients with uncontrolled essential hypertension: A prospective, observational study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Dong Kyun | - |
dc.contributor.author | Ahn, Joon Ho | - |
dc.contributor.author | Lee, Ki Hong | - |
dc.contributor.author | Kang, Si-Hyuck | - |
dc.contributor.author | Kim, Sung Soo | - |
dc.contributor.author | Na, Jin Oh | - |
dc.contributor.author | Park, Sang Don | - |
dc.contributor.author | Ahn, Kye Taek | - |
dc.contributor.author | Lee, Jung-Hee | - |
dc.contributor.author | Jung, In Hyun | - |
dc.contributor.author | Seo, Jongkwon | - |
dc.contributor.author | Choi, Woong Gil | - |
dc.date.accessioned | 2022-06-11T00:40:17Z | - |
dc.date.available | 2022-06-11T00:40:17Z | - |
dc.date.created | 2022-06-10 | - |
dc.date.issued | 2022-03 | - |
dc.identifier.issn | 1524-6175 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/141916 | - |
dc.description.abstract | Although amlodipine is recommended as the first-line therapy for the treatment of hypertension, its use is limited by its potential side effects. S-amlodipine is expected to be able to minimize side effects of amlodipine with a similar antihypertensive effect by removing the malicious R-chiral form. However, sustainable blood pressure control with S-amlodipine has not been well established yet. The purpose of the current study was to evaluate ambulatory blood pressure (ABP) profiles before and after a 12-week treatment of S-amlodipine. Patients received once-daily S-amlodipine 2.5 or 5 mg. ABP during 24 hr and office blood pressure were measured at baseline and after the 12-week treatment. Primary endpoints were changes of systolic and diastolic 24 hr ABP. After 12-week S-amlodipine treatment, mean systolic ABP (-15.1 +/- 16.2 mmHg, p < .001) and diastolic ABP (-8.9 +/- 9.8 mmHg, p < .001) were decreased significantly. Both daytime and night-time mean systolic BP and diastolic BP were also significantly decreased after the 12-week treatment. Global trough-to-peak ratio and smoothness index after 12-week S-amlodipine treatment were .75 and .79 for SBP and .65 and .61 for DBP, respectively. Age >= 65 years (hazard ratio [HR]: 3.13; 95% confidence interval [CI]: 1.67-14.3) and nonalcohol drinking (HR: 3.09; 95% CI: 1.34-7.17) were independent clinical factors for target ABP achievement. Adverse drug reactions (ADR) were developed in 16 (6.4%) patients, including two (.8%) cases of peripheral edema. In conclusion, this study demonstrated the efficacy and safety of S-amlodipine in patients with uncontrolled essential hypertension. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | TO-MODERATE HYPERTENSION | - |
dc.subject | PEAK RATIO | - |
dc.subject | SMOOTHNESS INDEX | - |
dc.subject | S(-)-AMLODIPINE NICOTINATE | - |
dc.subject | RACEMIC AMLODIPINE | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | TROUGH | - |
dc.subject | EFFICACY | - |
dc.subject | EDEMA | - |
dc.subject | TOLERABILITY | - |
dc.title | Ambulatory blood pressure response to S-amlodipine in Korean adult patients with uncontrolled essential hypertension: A prospective, observational study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Na, Jin Oh | - |
dc.identifier.doi | 10.1111/jch.14442 | - |
dc.identifier.scopusid | 2-s2.0-85124900549 | - |
dc.identifier.wosid | 000758230500001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL HYPERTENSION, v.24, no.3, pp.350 - 357 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL HYPERTENSION | - |
dc.citation.title | JOURNAL OF CLINICAL HYPERTENSION | - |
dc.citation.volume | 24 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 350 | - |
dc.citation.endPage | 357 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | TO-MODERATE HYPERTENSION | - |
dc.subject.keywordPlus | PEAK RATIO | - |
dc.subject.keywordPlus | SMOOTHNESS INDEX | - |
dc.subject.keywordPlus | S(-)-AMLODIPINE NICOTINATE | - |
dc.subject.keywordPlus | RACEMIC AMLODIPINE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | TROUGH | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | EDEMA | - |
dc.subject.keywordPlus | TOLERABILITY | - |
dc.subject.keywordAuthor | ambulatory | - |
dc.subject.keywordAuthor | blood pressure monitoring | - |
dc.subject.keywordAuthor | chirality | - |
dc.subject.keywordAuthor | essential hypertension | - |
dc.subject.keywordAuthor | S-amlodipine | - |
dc.subject.keywordAuthor | safety | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.